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The significance of ErbB4 in tumor biology is poorly understood. The ERBB4 gene is alternatively spliced producing
juxtamembrane (JM-a and JM-b) and cytoplasmic (CYT-1 and CYT-2) isoforms. Here, signaling via the two alternative
ErbB4 JM isoforms (JM-a CYT-2 and JM-b CYT-2) was compared. Fibroblasts expressing ErbB4 JM-a demonstrated
enhanced ErbB4 autophosphorylation, growth, and survival. In contrast, cells overexpressing ErbB4 JM-b underwent
starvation-induced death. Both pro- and antisurvival responses to the two ErbB4 isoforms were sensitive to an ErbB kinase
inhibitor. Platelet-derived growth factor receptor-alpha (PDGFRA) was identified as an ErbB4 target gene that was
differentially regulated by the two ErbB4 isoforms. The soluble intracellular domain of ErbB4, released from the JM-a but
not from the JM-b isoform, associated with the transcription factor AP-2 and promoted its potential to enhance PDGFRA
transcription. Survival of cells expressing JM-a was suppressed by targeting either PDGFR- or AP-2, whereas cells
expressing JM-b were rescued from cell death by the PDGFR- agonist, PDGF-BB. These findings indicate that two
alternative ErbB4 isoforms may promote antagonistic cellular responses and suggest that pharmacological inhibition of
ErbB4 kinase activity may lead to either suppression or promotion of cellular growth.
INTRODUCTION
ErbB/HER receptors form the epidermal growth factor re-
ceptor (EGFR) subfamily of receptor tyrosine kinases includ-
ing ErbB1 (EGFR, HER1), ErbB2 (c-Neu, HER2), ErbB3
(HER3), and ErbB4 (HER4). ErbB receptors consist of an
extracellular ligand-binding ectodomain, a hydrophobic
transmembrane domain, and an intracellular cytoplasmic
domain with enzymatic tyrosine kinase activity. Several
EGF-like growth factors, such as neuregulins (NRG), bind to
ErbB receptors, stimulating receptor dimerization, confor-
mational changes, and subsequent autophosphorylation of
tyrosine residues. These phosphorylation events trigger ac-
tivation of downstream signal transduction molecules that
couple ErbBs to cellular responses, such as proliferation,
differentiation, apoptosis, and survival. Overexpression and
mutations of ErbBs have been associated with malignant
growth. Moreover, drugs that target ErbB1 or ErbB2 have
demonstrated clinical effect as cancer therapeutics. These
drugs include anti-ErbB antibodies and small-molecular-
weight tyrosine kinase inhibitors (Hynes and MacDonald,
2009).
Relatively little is known about the cancer biology of
ErbB4. Overexpression of ErbB4 promotes breast cancer cell
proliferation and transforms fibroblasts (Cohen et al., 1996;
Tang et al., 1999; Maatta et al., 2006). In contrast, ErbB4
activation has also been suggested to induce differentiation
of breast cancer cells, confer cell cycle arrest, or stimulate
apoptosis (Chen et al., 1996; Jones et al., 1999; Ni et al., 2001;
Williams et al., 2004; Vidal et al., 2005; Muraoka-Cook et al.,
2006a,b). Interpretation of published results has been com-
plicated by the existence of four structurally and function-
ally different ErbB4 isoforms. These isoforms are generated
from a single ERBB4 gene by tissue-specific alternative splic-
ing (Junttila et al., 2000, 2003). The isoforms are all functional
and tyrosine phosphorylated upon treatment with NRG-1
(Maatta et al., 2006). ErbB4 juxtamembrane (JM) isoforms
(JM-a and JM-b) differ in their susceptibility to proteolysis at
the extracellular JM domains (Elenius et al., 1997). As a
consequence, only JM-a isoforms with 23 unique amino
acids within the JM domain undergo ectodomain shedding,
whereas JM-b isoforms with 13 alternative amino acids at
the JM domain do not (Elenius et al., 1997). ErbB4 cytoplas-
mic (CYT) isoforms differ at cytoplasmic tails by including
(CYT-1) or not (CYT-2) a 16-amino acid stretch containing
binding sites for phosphoinositide 3-kinase (PI3-K; Elenius
et al., 1999; Kainulainen et al., 2000), as well as for WW
domain-containing proteins such as Nedd-like ubiquitin li-
gases (Omerovic et al., 2007; Sundvall et al., 2008b; Feng et al.,
2009; Zeng et al., 2009).
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In addition to activating cascadical signaling pathways
such as Ras–Raf–MAP/ERK kinase (Mek) –mitogen-acti-
vated protein kinase (MAPK) and PI3K/Akt (Kainulainen et
al., 2000), the intracellular domains (ICD) of proteolytically
processed ErbB4 isoforms have been shown to directly
translocate into the nucleus and regulate transcription (Ni et
al., 2001; Lee et al., 2002; Komuro et al., 2003; Williams et al.,
2004; Maatta et al., 2006; Sardi et al., 2006). First, ErbB4 JM-a
is cleaved by tumor necrosis factor- converting enzyme
(TACE) approximately eight amino acids N-terminal to the
transmembrane domain (Elenius et al., 1997; Rio et al., 2000;
Cheng et al., 2003). Subsequently, the remaining N-terminally
truncated receptor undergoes regulated intramembrane prote-
olysis (RIP) by -secretase activity creating a soluble ICD frag-
ment that may function as a transcriptional coregulator for
several regulators of transcription, such as STAT5A, estrogen
receptor-, ETO2, and YAP-2 (Jones, 2008).
Previous findings have supported differential roles for
different ErbB4 isoforms in cancer biology. CYT isoforms
differ in subcellular targeting and stability (Maatta et al.,
2006; Sundvall et al., 2007; Sundvall et al., 2008b) and have
opposing effects on mouse mammary epithelium in vivo.
ICD of CYT-1 type decreases mammary epithelial growth,
whereas ICD of CYT-2 type causes epithelial hyperplasia
(Muraoka-Cook et al., 2009). Only cleavable ErbB4 JM-a
CYT-2 capable of releasing a soluble ICD promotes survival
of myeloid cells and growth of breast cancer cells in vitro
(Maatta et al., 2006). In addition, nuclear localization of
ErbB4 epitope associates with worse survival than localiza-
tion of ErbB4 at the cell surface (Junttila et al., 2005).
Here, we compared the transforming potential of two
ErbB4 isoforms in stably transfected mouse NR6 fibroblasts,
a well-characterized model of ErbB-induced transformation
(Chazin et al., 1992; Carey et al., 2006). Consistent with earlier
analyses with other models (Junttila et al., 2005; Maatta et al.,
2006), the JM-a CYT-2 isoform promoted proliferation, sur-
vival, and anchorage-independent growth. However, cells
expressing ErbB4 JM-b CYT-2 with an alternative JM do-
main stimulated, rather than suppressed, apoptosis. Both
responses were sensitive to an ErbB kinase inhibitor, indi-
cating that ErbB4 inhibition can either promote or suppress
growth, depending on the isoform expressed by the target
cell. Further analyses on the mechanisms underlying the
responses demonstrated a role for differential regulation of
the PDGFRA gene at the transcriptional level. These findings
suggest that the two ErbB4 isoforms may stimulate opposite
cellular responses and underline the importance of using
isoform-specific reagents when analyzing the potential of
ErbB4 as a cancer drug target.
MATERIALS AND METHODS
Stable Transfectants
NR6 mouse fibroblasts (Pruss and Herschman, 1977) were maintained in
DMEM (Invitrogen, Carlsbad, CA) supplied with 10% fetal calf serum (FCS;
PromoCell GmbH, Heidelberg, Germany). Cells were transfected with
pcDNA3.1ErbB4JM-aCYT-2 or pcDNA3.1ErbB4JM-bCYT-2 expression con-
structs (Maatta et al., 2006) using Lipofectamine plus transfection reagent
(Invitrogen) according to manufacturer’s instructions. Stable clones were
selected and cultured in the presence of 500 g/ml G418 (geneticin; Calbio-
chem, La Jolla, CA). ErbB4 protein expression was analyzed as described
below.
Chemical Inhibitors and RNA Interference
Inhibitors for ErbB receptors (AG 1478) and PDGFR (AG 1296) were
purchased from Calbiochem. siRNAs targeting AP-2 (Hs_TFAP2A_5),
Mek1 (Hs_MAP2K1_6), Erk1/2 (Hs_MAPK1_10), Sp1 (Hs_SP1_5), Oct-1
(Hs_POU2F1_2), or a nonsilencing control siRNA were purchased from Qia-
gen (Chatsworth, CA). siRNA sequences are listed in Supplemental Table 1.
siRNA specific for ErbB4 JM-a and control siRNA specific for the JM-b isoform
(not expressed in MCF-7 cells), have been previously described (Maatta et al.,
2006). siRNAs were transfected to cells using Lipofectamine 2000 (Invitrogen)
according to the manufacturer’s instructions. The knockdown efficiency of RNA
interference was determined by real-time RT-PCR as described below.
Western Blotting and Protein Phosphorylation Analyses
For ErbB4 and PDGFR- protein expression analysis, NR6 transfectants were
lysed, and samples equivalent to 75 g of total protein were separated in 8%
SDS-PAGE gels followed by Western blotting with anti-ErbB4 antibody (sc-
283; Santa Cruz Technology, Santa Cruz, CA) or polyclonal anti-PDGFR-
antibody (Cell Signaling Technology, Beverly, MA) as previously described
(Kainulainen et al., 2000).
For analysis of protein phosphorylation status, cells were starved overnight
in DMEM containing no FCS and stimulated for 10–40 min with or without
recombinant human NRG-11 (50 ng/ml; R&D Systems, Minneapolis, MN).
For analysis of ErbB4 and PDGFR- tyrosine phosphorylation, 1 mg of total
protein lysate was immunoprecipitated with an anti-ErbB4 antibody (sc-283)
or anti-PDGFR- antibody (Cell Signaling Technology) and analyzed by
Western blotting using an anti-phosphotyrosine antibody (4G10; Upstate
Biotechnology, Lake Placid, NY), as previously described (Maatta et al., 2006).
Filters were reblotted with anti-ErbB4 (sc-283) or anti-PDGFR- (Cell Signal-
ing Technology) to control loading. For analysis of Erk, Akt, and p38 phos-
phorylation, samples equivalent to 75 g of total protein were separated in 8
or 10% SDS-PAGE gels followed by Western blotting with anti-phospho-
p44/42 MAPK (Thr202/Tyr204; Cell Signaling Technology), anti-phospho-
Akt (Ser 473; Cell Signaling Technology), and anti-phospho-p38 MAPK
(Thr180/Tyr182; Zymed Laboratories, South San Francisco, CA) antibodies. To
control loading, membranes were stripped and reblotted with anti-p44/42 (Cell
Signaling Technology), anti-Akt (sc-1618; Santa Cruz), anti-p38 MAPK (Zymed
Laboratories) or anti-actin (sc-1616; Santa Cruz Technology) antibodies.
Kinase activity of ErbB4 JM-a CYT-2 and JM-b CYT-2 in NR6 cells was
analyzed using in vitro kinase assays as previously described (Maatta et al.,
2006).
Proliferation Analyses
For cell-counting experiments, NR6 transfectants were plated on 24-well
plates at a density of 50,000 cells/well in DMEM containing 10% FCS. The
following day, the media were replaced by DMEM containing 0–5% FCS
supplemented with or without NRG-1 (50 ng/ml) or PDGF-BB (50 ng/ml;
PeproTech, Rocky Hill, NJ). At days 2–5 after initial plating, cells were
visualized and photographed under a phase-contrast microscope, washed
with PBS, removed with trypsin, and counted under a microscope with
hemocytometer. Analyses were carried out in triplicates. When inhibitors
were used, they were added 24 h after plating in serum-free culture medium.
Data were statistically analyzed using Student’s t test.
For MTT proliferation assays, NR6 transfectants expressing ErbB4 JM-a
CYT-2 or JM-b CYT-2 were plated onto 96-well plates in triplicates in DMEM
containing 10% FCS. The next day, 150 nM siRNA targeting AP-2 or a
nonsilencing control siRNA were transfected to cells. The number of viable
cells was estimated 1, 2, or 3 d after initiation of the starvation using a
CellTiter 96 nonradioactive cell proliferation assay (MTT; Promega, Madison,
WI). Data were statistically analyzed using Student’s t test.
Soft Agar Colony Formation Assay
Bottom layers (2 ml) composed of DMEM containing 0.5% agar (Bacto-agar;
Difco, Detroit, MI), 10% FCS, and 1% l-glutamine-penicillin-streptomycin
(GPS) solution were prepared into six-well plate wells. Top layers (1.2 ml)
consisting of 30,000 NR6 transfectants and DMEM containing 0.33% agar, 10%
FCS, 1% GPS, and 0 or 100 ng/ml NRG-1 were added onto the solidified
bottom layers. After 3 d of incubation, 200 l per well of fresh DMEM
supplemented with 10% FCS and 1% GPS was added on wells to maintain
humidity. Cells were incubated at 37°C for up to 7 wk and photographed
under a phase-contrast microscope. Data were statistically analyzed using
ANOVA (Dunnett T3 posthoc t tests).
Cell Cycle Analysis
NR6 transfectants were starved without serum for 72 h. Subsequently, both
adherent and floating cells were harvested, washed with PBS, and fixed with
70% ethanol at 20°C for 20 min. Fixed samples were washed with PBS, and
treated with RNAse A (0.15 mg/ml; Sigma, St. Louis, MO), and DNA was
stained with propidium iodine (PI; 40 g/ml; Sigma). DNA content per
particle was determined with FACSCalibur (BD Bioscience, San Jose, CA).
Data were analyzed using CellQuest Prosoftware (BD).
TUNEL and DAPI Staining
NR6 transfectants were plated onto 13-mm coverslips at a density of 70,000
cells per milliliter of DMEM containing 10% FCS. The next day the cells were
washed with DMEM, and the media were replaced by DMEM containing no
serum. Cells were starved without serum for 2 d, washed with PBS, and fixed
with methanol. DNA strand breaks were stained with TUNEL (TdT-mediated
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dUTP nick end labeling) staining reagent according to manufacturer’s instruc-
tions (In Situ Cell Death Detection Kit, TMR red; Roche, Indianapolis, IN). To
analyze nuclear morphology, nuclei were stained with 0.5 g/ml DAPI
(4,6-diamidino-2-phenylindole; Sigma) in PBS containing 3% bovine serum
albumin for 10 min at room temperature. After staining, coverslips were
washed with PBS and H2O and mounted with Vectashield mounting medium
(Vector Laboratories, Burlingame, CA). Cells were photographed and
counted under a fluorescence microscope. The percentage of condensed nu-
clei to all nuclei was determined from at least five arbitrary fields. Experi-
ments were repeated at least three times.
cDNA Microarrays
For cDNA microarray analyses, NR6 transfectants were starved without
serum for 8 h and treated with or without NRG-1 (50 ng/ml) for 2 h. Vector
control cells without NRG-1 treatment were used as a reference sample. RNA
was extracted with TRIzol (Invitrogen) and purified with RNeasy MinElute
Cleanup Kit (Qiagen). The quality of the RNA samples was determined by
spectrophotometry (NanoDrop ND-1000; NanoDrop Technologies, Wilming-
ton, DE), gel electrophoresis, and by analyzing -actin expression by real-time
RT-PCR (Iivanainen et al., 2003; Junttila et al., 2003). Only samples of uniform
quality were chosen for cDNA microarray experiments. The samples were
amplified with Ribo Amp RNA Amplification Kit (Arcturus Bioscience,
Mountain View, CA).
Twenty micrograms of each RNA sample was labeled, and hybridization
was carried out as previously described (Nikula et al., 2005), with the excep-
tion that hybridization chambers were purchased from TeleChem Interna-
tional (Sunnyvale, CA). The arrays contained 15,000 mouse genes from the
National Institute on Aging NIH mouse library spotted in duplicate on
poly-l-lysine coated glass slides (Finnish DNA Microarray Centre, Turku,
Finland). Microarray data were extracted and normalized using Scan-Array
Express software (v.2.1.8; Perkin-Elmer, Waltham, MA), as described (Nikula
et al., 2005). The sample expression level at each spot on the array was
compared with the expression level of the reference sample, and qualita-
tively poor spots were discarded. A gene was considered as differentially
expressed only if data were obtained from both spots and there was at
least a 2.0-fold change in the average expression level. The results were
analyzed with Kensington Discovery Edition software (v.2.0.4; InforSense
Cambridge, MA) and DAVID (Database for Activation, Visualition, and
Integrated Discovery; Functional Annotation Bioinformatics Microarray
Analysis; http://david.abcc.ncifcrf.gov/).
RT-PCR
cDNA microarray data were confirmed by RT-PCR. RNA was isolated and
reverse-transcribed as described before (Junttila et al., 2003). PDGFRA tran-
scripts were analyzed with primers listed in Supplemental Table 1. To control
for mRNA quality, primers specific for -actin (Iivanainen et al., 2003) were
used. PCR reactions were carried out in a total volume of 30 l, containing
0.67 M primers, 3 l of 10 Mg2-free DyNAzyme buffer (Finnzymes,
Espoo, Finland), 500 M of each dNTP (Finnzymes), 1 U of DyNAzyme II
EXT DNA Polymerase (Finnzymes), and 1 l of template cDNA or water
(negative control). PCR samples were denatured at 94°C for 3 min and
subsequently cycled 25 times (-actin) or 35 times (PDGFR) through 1-min
steps of annealing at 60°C, extension at 72°C, and denaturation at 94°C. PCR
products were separated by electrophoresis using 2% agarose gels, stained
with ethidium bromide, and visualized with UV light.
Real-time RT-PCR analysis of ErbB4 expression was carried out as de-
scribed (Junttila et al., 2003, 2005), except that ABI Prism 7500 or 7900HT
Sequence Detectors (Applied Biosystems. Foster City, CA) were used. For
amplification of other transcripts, primers and probes listed in Supplemental
Table 1 were used.
PDGFRA Promoter Assay
The effect of ErbB4 signaling on PDGFRA promoter activity was analyzed
in MCF-7 cells, which endogenously express ErbB4 JM-a CYT-1 and JM-a
CYT-2 isoforms (Maatta et al., 2006). The cells were plated on 24-well plates
and cotransfected with pEGFP-C3 (polymeric enhanced green fluorescent
protein [pEGFP]; Clontech, Palo Alto, CA) and constructs expressing
luciferase reporter driven by PDGFRA promoter fragments of different
sizes (pSLA4PDGFRluc–441/118, pSLA4PDGFRluc–944/118, and
pSLA4PDGFRluc–1253/118; Afink et al., 1995) using Lipofectamine 2000
(Invitrogen). Starting 30 h after transfection, the cells were starved in the
absence of serum for 16 h and stimulated for 2 h with 80 ng/ml NRG-1 or for
18 h with 10 M retinoic acid (RA). The fluorescence signal of EGFP was used
to normalize the luminescence signal generated by the luciferase reporters as
previously reported (Sundvall et al., 2007). To assess the effect of AP-2 and
ErbB4 ICD overexpression on PDGFRA promoter, vector control, pCMVHA-
AP2, pCMVHA-AP2 (Aqeilan et al., 2004a), and/or pcDNA3.1ErbB4ICD2
(Sundvall et al., 2007), constructs were expressed with pSLA4PDGFRluc–
1253/118 and pRL-TK Renilla luciferase (Stratagene, La Jolla, CA) reporter
constructs in human embryonic kidney (HEK)-293T cells. Dual Luciferase
Reporter Assay (Promega) was used to measure luciferase activities. For RNA
interference analyses, siRNAs were transfected to cells as above 4 h after
transfecting the luciferase and EGFP constructs. A minimum of six indepen-
dent experiments was carried out for all promoter assays, and the statistical
significance was determined with one-way ANOVA (Dunnett two-sided or
Dunnett T3 posthoc t tests).
Confocal Microscopy
COS-7 cells were transiently transfected with constructs encoding hemagglu-
tinin (HA)-tagged ErbB4 JM-b CYT-2 or the sole intracellular domain of the
CYT-2-type, fixed 24 h after transfection, and stained with rat anti-HA anti-
body (epitope 12CA5; Zymed) and mouse monoclonal anti-AP-2 antibody
(sc-25343; Santa Cruz Biotechnology), as previously described (Sundvall et al.,
2008b).
Coimmunoprecipitation of ErbB4 with AP-2
Interaction between full-length or ICD of ErbB4 and AP-2 was determined by
coimmunoprecipitation analysis of COS-7 cell transfectants, as previously
described (Sundvall et al., 2008b). Constructs encoding HA-tagged ErbB4
JM-b CYT-2 or the sole intracellular domain of the CYT-2-type (Sundvall et al.,
2007) and Myc-tagged AP-2 or AP-2 (Aqeilan et al., 2004a) were used.
Glutathione S-transferase Pulldown Assay
To generate glutathione S-transferase (GST) fusion constructs encoding either
ICD of the CYT-2-type (ICD2), N-terminally truncated ICD2 (ICD-N, includ-
ing amino acids 997-1292) or C-terminally truncated ICD2 (ICD-C; amino
acids 676-996), pcDNA3.1ErbB4ICD2 (Sundvall et al., 2007) was amplified
with primers (Supplemental Table 1) including sites for restriction enzymes.
The PCR products were ligated into a pGEX6p-1 vector (GE Healthcare-
Waukesha, WI) using SalI and NotI restriction sites. For GST pulldown
assays, Myc-tagged AP-2 (Aqeilan et al., 2004a) or Myc-tagged Wwox
(Aqeilan et al., 2004b) constructs were expressed in COS-7 cells, and the
interaction between AP-2 or Wwox and the GST fusion proteins was ana-
lyzed as previously described (Sundvall et al., 2008b).
RESULTS
NR6 Transfectants Expressing ErbB4 JM-a CYT-2 and
ErbB4 JM-b CYT-2
NR6 cells are a population of Swiss 3T3 fibroblasts that was
originally selected for a lack of EGF response and are devoid
of EGFR (Pruss and Herschman, 1977). NR6 cells also lack
endogenous ErbB3 and ErbB4 and express only ErbB2 (data
not shown). Moreover, NR6 cells have successfully been
used to analyze transforming potential of ErbBs (Chazin et
al., 1992; Carey et al., 2006). Because only nonadherent he-
matopoietic cells totally lack ErbB2 (Maatta et al., 2006), NR6
cells represent a model to analyze transforming activity of
ErbB4 isoforms in a cell background with minimal endoge-
nous ErbB expression.
NR6 cells were stably transfected to overexpress two
ErbB4 isoforms with the same CYT-2 domain but different
JM domains (JM-a CYT-2 and JM-b CYT-2). The JM-a CYT-2
isoform was chosen as it has previously been shown to be
the most potent ErbB4 isoform in stimulating ligand-inde-
pendent survival of myeloid 32D cells (Maatta et al., 2006)
and growth of MCF-7 breast cancer cells (Junttila et al., 2005;
Maatta et al., 2006). As the ligand-independent responses to
JM-a CYT-2 expression have been shown to be partially
dependent on cleavage of a soluble ICD by RIP (Maatta et al.,
2006), the noncleavable JM-b CYT-2 was included in the
experiments for comparison. Several independent transfec-
tant clones were established and screened for ErbB4 expres-
sion by Western blotting (Figure 1A; Supplemental Figure
1). In all ErbB4 transfectants a 180-kDa band representing the
full-length ErbB4 was visible. An 80-kDa fragment represent-
ing the carboxy-terminal cleavage product of ErbB4 was con-
stitutively generated in cells expressing ErbB4 JM-a CYT-2, but
not in cells expressing ErbB4 JM-b CYT-2. Both ErbB4 isoforms
were tyrosine-phosphorylated upon NRG-1 stimulation, but
only JM-a CYT-2 demonstrated efficient constitutive phosphor-
ylation in the absence of ligand stimulation (Figures 1B and
5B). Furthermore, the 80-kDa fragment of ErbB4 JM-a CYT-2
demonstrated high basal tyrosine phosphorylation (Figures 1B
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and 5B). These findings are consistent with our previous ob-
servations in other cell backgrounds (Maatta et al., 2006) and
demonstrate that JM-a CYT-2 but not JM-b CYT-2 is constitu-
tively processed to generate an 80-kDa phosphorylated car-
boxy-terminal fragment in NR6 cells.
ErbB4 JM-a CYT-2 Has Efficient Autokinase Activity
Differential tyrosine phosphorylation of the two isoforms
could result from differences in intrinsic kinase activities
between the two proteins. To address the relative kinase
activities, both isoforms were immunoprecipitated from
NR6 cells and subjected to in vitro kinase assay in the
presence of ATP. Both isoforms demonstrated basal autoki-
nase activity (Figure 1C). However, the activity of the 180-kDa
JM-a CYT-2 was on average twice the activity observed for
180-kDa JM-b CYT-2, after normalizing for ErbB4 protein ex-
pression. In addition, enhanced autokinase-stimulated phos-
photyrosine content of the 80-kDa JM-a CYT-2 fragment was
observed. However, chemical inhibition of ErbB4 cleavage by
blocking either TACE or -secretase activity did not reduce the
basal 180-kDa JM-a CYT-2 tyrosine phosphorylation, suggest-
ing that proteolytic production of an active 80-kDa fragment
was not necessary for phosphorylation of the full-length recep-
tor (data not shown). These findings demonstrate a difference
between kinase activities of the two ErbB4 isoforms.
Signal Transduction Pathways Activated by JM-a CYT-2
and JM-b CYT-2
Differences in the activation patterns and kinetics of signal-
ing pathways, such as Mek/Erk pathway associate with
different cellular responses, such as proliferation versus dif-
ferentiation (Marshall, 1995). To test whether isoform-spe-
cific characteristics associated with differential intracellular
signaling, NR6 transfectants were stimulated with NRG-1
and analyzed by Western blotting using phospho-specific
antibodies for the MAPKs Erk1/2, and p38, as well as Akt
(Figure 1D). Both isoforms were capable of activating
Erk1/2, although the phosphorylation stimulated by JM-a
CYT-2 seemed to be sustained somewhat longer. Neither of
the isoforms activated p38. In line with earlier findings
(Kainulainen et al., 2000), activation of Akt, a downstream
target of PI3-K, was relatively weak by both of the CYT-2
isoforms lacking the direct PI3-K docking site (Elenius et al.,
1999). These findings suggest that, with the exception of
differences in the kinetics of Erk activation, the two ErbB4s
did not significantly differ in stimulating some of the major
signal transduction pathways involved in ErbB-regulated
proliferation and survival.
ErbB4 JM-a CYT-2 Promotes Proliferation and
Anchorage-independent Growth
To test whether JM-a CYT-2 and JM-b CYT-2 expression
affected proliferation, growth curves were generated for
transfectants maintained in DMEM containing 5% FCS. An
increase in proliferation was evident in cells expressing JM-a
CYT-2 when compared with vector transfectants (Figure
2A). JM-b CYT-2 expression had no effect on cell numbers in
the presence of 5% FCS (Figure 2A). To analyze the potential
of the isoforms to induce anchorage-independent growth,
transfectants were seeded in soft agar. Cells expressing JM-a
Figure 1. Expression and activity of ErbB4
isoforms in NR6 cells. (A) Expression of ErbB4
protein in NR6 transfectants was analyzed by
Western blotting. (B) Cells were starved over-
night without serum and stimulated with or
without 50 ng/ml NRG-1 for 10 min. ErbB4
tyrosine phosphorylation was analyzed by im-
munoprecipitation with an anti-ErbB4 antibody
followed by Western blotting with an anti-
phosphotyrosine antibody. Membrane was re-
blotted with an anti-ErbB4 antibody. (C) For in
vitro kinase assay, cell lysates were immunopre-
cipitated with an anti-ErbB4 antibody, incubated
with ATP, and analyzed for ErbB4 tyrosine
phosphorylation by immunoprecipitation with
anti-ErbB4 antibody followed by Western blot-
ting with an anti-phosphotyrosine antibody.
(D) Cells were starved overnight and stimu-
lated with or without NRG-1 for indicated time
periods. Phosphorylation of Erk, Akt, and p38
was analyzed by Western blotting with phos-
phospecific antibodies. Subsequently, mem-
branes were reblotted with anti-Erk, anti-Akt,
anti-p38, or anti-actin antibodies.
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CYT-2 formed significantly more colonies than cells express-
ing JM-b CYT-2 or vector control cells (Figure 2, B and C).
These data suggest that ErbB4 JM-a CYT-2, but not JM-b
CYT-2, promotes growth of NR6 cells in soft agar.
ErbB4 JM-b CYT-2 Promotes Starvation-induced Cell
Death
To compare the effect of ErbB4 isoform expression on cells
progressing in cell cycle or induced into quiescence, NR6
transfectants were grown in the presence or absence of
serum. All transfectants displayed normal fibroblast morphol-
ogy when cultured in 10% FCS (Figure 3A). However, cells
expressing JM-a CYT-2 preserved their normal morphology
longer than vector control cells under serum-free conditions.
Interestingly, cells expressing JM-b CYT-2 seemed to lose
their spindle-shaped morphology and detach from the cul-
ture plates clearly before the vector control cells (Figure 3A).
Consistent with the morphological differences, JM-a CYT-2
expression stimulated resistance to starvation-induced de-
cline in cell numbers (Figure 3B). In contrast, expression of
JM-b CYT-2 induced a rapid loss of all adherent cells when
grown in medium containing 1 or 0% FCS (Figure 3B).
Similar results were obtained with independent clones and
when the cells were treated with different concentrations
of the ErbB4 ligand NRG-1 (Supplemental Figure 2).
Taken together, these data suggest that ErbB4 JM isoforms
confer opposite cellular responses to serum deprivation:
JM-a CYT-2 promotes resistance but JM-b CYT-2 sensitiv-
ity to cell death.
Cells Expressing ErbB4 JM-b CYT-2 Have Characteristics
of Apoptosis
To characterize the mechanism leading to facilitated death of
cells expressing ErbB4 JM-b CYT-2 under serum depriva-
tion, DNA content of transfectants was analyzed by fluores-
cent-activated cell sorting (FACS). After 3 d of starvation,
the subG1 population with small DNA content was consid-
erably greater in cells expressing JM-b CYT-2 when com-
pared with other transfectants (Figure 4A), consistent with
apoptosis. Within 2 d after serum deprivation the nuclei in
43% of the vector control cells gained morphological char-
acteristics of apoptosis (Figure 4, B and C). The percentage
of cells with apoptotic changes was more than doubled to
91% in cells expressing JM-b CYT-2, but was only 13% in
cells expressing JM-a CYT-2 (Figure 4, B and C). Con-
densed nuclei demonstrated by bright DAPI staining were
also almost exclusively TUNEL positive (Figure 4B).
These data indicate that cells expressing ErbB4 JM-b
CYT-2 die because of apoptosis-like mechanisms in re-
sponse to serum deprivation.
Chemical ErbB Kinase Inhibitor Reverses Both ErbB4
Isoform-specific Responses to Serum Deprivation
To test whether ErbB4 kinase activity was necessary for the
two opposite cellular responses stimulated by the two ErbB4
isoforms upon starvation, NR6 transfectants were cultured
under serum-free conditions in the presence and absence of
a chemical ErbB kinase inhibitor AG 1478. Addition of AG
1478 significantly inhibited the growth of cells expressing
JM-a CYT-2 (Figure 5A). No significant effect on growth was
observed in vector control cells (data not shown). Signifi-
cantly, adding AG 1478 into cells expressing JM-b CYT-2
partially rescued them from apoptosis (Figure 5A). The ef-
fect of AG 1478 on blocking both basal and ligand-induced
tyrosine phosphorylation of both ErbB4 isoforms was dem-
onstrated by Western analysis (Figure 5B). These findings
suggest that both the pro- and antisurvival responses were
at least partially dependent on ErbB4 kinase activity. The
observation also indicates that inhibition of ErbB4 kinase
activity may result in either promotion or suppression of
apoptosis, depending on the isoforms present on the tar-
geted cell. Similar findings with AG 1478 were also made in
analyses of MCF-7 breast cancer cell transfectants expressing
either JM-a CYT-2 or JM-b CYT-2 isoforms (data not shown).
Regulation of PDGFRA Expression by ErbB4 Isoforms
To identify molecular mechanisms underlying the different
cellular responses promoted by the two ErbB4 isoforms, a
cDNA microarray including 15,000 mouse cDNAs was
screened for genes regulated in an ErbB4 isoform-specific
manner. The cDNA array analysis indicated that ErbB4 JM-a
CYT-2 and ErbB4 JM-b CYT-2 indeed regulated different sets
of genes (Supplemental Table 2). One of the identified genes,
PDGFRA, was up-regulated by JM-a CYT-2 but down-reg-
ulated by JM-b CYT-2. The finding was confirmed by RT-
PCR analysis of PDGFRA mRNA (Figure 6A) and Western
analysis of PDGFR- protein (Figure 6C). Consistent with
Figure 2. Growth of NR6 cells expressing ErbB4 isoforms. (A) NR6
transfectants were plated onto 24-well plates in the presence of 10%
FCS. The next day the medium was replaced with medium contain-
ing 5% FCS with or without 50 ng/ml NRG-1. Adherent cells were
counted at indicated time points with hemocytometer. *p  0.05 for
a difference between ErbB4 overexpression versus vector in the
presence of NRG-1. (B and C) Cells were cultured in soft agar for 7
wk. Representative images (B) and quantitation of colonies (C) are
shown.
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the regulation taking place at the level of transcription, no
differences in the relative degradation rate of the PDGFR-
protein, or the expression of the known PDGFR E3 ubiquitin
ligase, Cbl, were observed between the transfectants (data
not shown).
Because the antagonistic cellular responses stimulated by
the two ErbB4 isoforms were both sensitive to AG 1478, the
effect of the kinase inhibitor was also tested on isoform-
regulated PDGFRA mRNA expression (Figure 6B). As ex-
pected, AG 1478 reduced PDGFRA mRNA expression in
cells expressing JM-a CYT-2 but induced PDGFRA expres-
sion in cells expressing JM-b CYT-2. Analysis of PDGFR-
protein expression in transfectants cultured overnight in the
presence or absence of FCS also demonstrated that starva-
tion alone induced PDGFR- expression, and expression of
JM-a CYT-2 facilitated this induction, whereas expression of
JM-b CYT-2 suppressed it (Figure 6C). These data suggest
that ErbB4 isoforms regulate different sets of genes and
identify PDGFRA as one gene that is regulated in opposite
directions by ErbB4 JM-a CYT-2 and JM-b CYT-2.
PDGFR- Has a Functional Role on the Pathway Leading
to Different Cellular Responses Downstream of the Two
ErbB4 Isoforms
The amount of tyrosine phosphorylated PDGFR- followed
the changes in total PDGFR- expression in the transfectants
(Figure 6D), suggesting functional significance. To further
evaluate the functional contribution of PDGFR- in regulat-
Figure 3. The effect of serum starvation on
cells expressing ErbB4 isoforms. (A) NR6
transfectants were cultured for 2 d in medium
containing 0 or 10% of FCS and photo-
graphed. (B) NR6 transfectants were plated
onto 24-well plates in the presence of 10%
FCS. The next day the medium was replaced
with medium containing 0, 1, or 2.5% FCS
with or without 50 ng/ml NRG-1. Adherent
cells were counted at indicated time points
with hemocytometer. *p  0.05 for a differ-
ence between ErbB4 overexpression versus
vector in the presence of NRG-1.
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ing different cellular responses to the two ErbB4 isoforms,
serum-starved NR6 transfectants were treated with the
PDGFR kinase inhibitor AG 1296 or with the PDGFR ligand
PDGF-BB (Figure 6E). AG 1296 reduced the number of cells
expressing JM-a CYT-2, whereas PDGF-BB rescued cells ex-
pressing ErbB4 JM-b CYT-2 from starvation-induced death.
The effect of AG 1296 on blocking the tyrosine phosphory-
lation of PDGFR- but not of ErbB4 JM-a was confirmed by
Western analysis (Figure 6F).
Taken together, these findings indicate that ErbB4 iso-
forms may mediate opposite cellular responses. The data
also suggest that differential regulation of PDGFRA gene is a
central mechanism involved in isoform-specific regulation
of cell behavior in fibroblasts.
Regulation of PDGFRA Promoter Activity by ErbB4
Targeting ERBB4 by RNA interference (73% knockdown as
estimated by real-time RT-PCR from parallel samples) sig-
nificantly suppressed the expression of PDGFRA mRNA in
SK-N-MC neuroblastoma cells that naturally overexpress
constitutively active ErbB4 JM-a isoforms (Figure 7A), dem-
onstrating transcriptional regulation of PDGFRA expression
also by endogenous ErbB4. To address the mechanism by
which stimulation of endogenous ErbB4 JM-a regulates
PDGFRA promoter activity, MCF-7 breast cancer cells (that
express JM-a CYT-1 and JM-a CYT-2; Maatta et al., 2006)
were transfected with luciferase reporter gene constructs
encoding PDGFRA promoter fragments of different sizes.
NRG-1 stimulation enhanced the promoter activity of the
longest construct (1253 base pairs upstream of the transcrip-
tion start site) by 50% (Figure 7B). An increase ranging
between 45 and 85% was achieved with all the promoter
constructs when cells were stimulated with 10 M retinoic
acid, a positive control known to promote PDGFRA expres-
sion (Figure 7B; Wang et al., 1990). The NRG-1–induced
Figure 4. Starvation-induced death of NR6 cells expressing ErbB4
isoforms. (A) Cells were cultured for 72 h in the absence of FCS, and
their DNA contents were analyzed by PI staining and FACS. The
proportion of cells containing subG1 quantities of DNA per particle
is indicated. (B) Cells were stained with TUNEL (red) and DAPI
(blue) after starvation for 2 d and photographed under a fluores-
cence microscope. (C) The percentage of condensed nuclei stained
with DAPI was calculated from five arbitrary fields per cell line
under a microscope.
Figure 5. The effect of inhibition of ErbB tyrosine kinase activity on
cells expressing ErbB4 isoforms. (A) NR6 cells expressing JM-a
CYT-2 or JM-b CYT-2 were plated onto 24-well plates in the pres-
ence of 10% FCS. The next day the medium was replaced with
serum-free medium containing 0 or 10 M of the ErbB kinase
inhibitor AG 1478. Adherent cells were counted at indicated time
points with hemocytometer. *p  0.05 for a difference between AG
1478-treated and control cells. (B) Cells were starved overnight
without serum, treated for 6 h with 0 or 10 M AG 1478, and
stimulated for 15 min with 0 or 50 ng/ml NRG-1. ErbB4 tyrosine
phosphorylation was analyzed by immunoprecipitation with an
anti-ErbB4 antibody followed by Western blotting with an anti-
phosphotyrosine antibody. Two different exposures of the phospho-
tyrosine blot are shown. Membrane was reblotted with an anti-
ErbB4 antibody. Binding of the anti-phosphotyrosine antibody 4G10
masks the epitope for the anti-ErbB4 sc-283, resulting in an appar-
ently reduced ErbB4 signal for the heavily phosphorylated ErbB4
species in the reblot (lanes 1 and 3).
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PDGFRA promoter activity in MCF-7 cells was blocked to
the level of nonstimulated control by siRNA targeting en-
dogenous ErbB4 (JM-a isoform-specific siRNA, 63% knock-
down) but not by control siRNA (Figure 7C).
Previous reports have indicated that PDGFRA promoter
contains putative binding sites for transcription factors such
as Sp-1, AP-2, and Oct-1 (Afink et al., 1995; Kawagishi et al.,
1995). To determine factors involved in ErbB4-mediated
PDGFRA regulation, the effects of specific siRNAs were
tested on NRG-1–stimulated PDGFRA promoter activity in
MCF-7 cells (Figure 7D). siRNA targeting Oct-1 did not
significantly affect the induction of the promoter activity by
NRG-1, whereas AP-2 siRNA suppressed it compared with
nonspecific control siRNA (Figure 7D). In contrast, the effect
of NRG-1 was enhanced in the presence of siRNA targeting
Sp1 by about fivefold (Figure 7D). Because Sp1-mediated
suppression of PDGFRA promoter activity in response to
fibroblast growth factor-2 (FGF-2) has been shown to in-
volve the Mek/Erk-pathway (Bonello and Khachigian,
2004), siRNAs targeting Mek1 or Erk1/2 were also tested.
Down-regulation of either Mek1 or Erk transcripts led to a
similar about threefold induction in NRG-1–induced PDGFRA
promoter activity (Figure 7D). Taken together these data
suggest that, although the net effect of stimulating endoge-
nous PDGFRA promoter by activating ErbB4 JM-a was pos-
itive, the promoter was regulated by both repressive as well
as enhancing signals.
AP-2 Solely Interacts with Soluble ICD of ErbB4
As AP-2 was identified as a transcription factor positively
regulating PDGFRA promoter in cells expressing ErbB4 JM-a
(Figure 7D), and the cleavable ErbB4 isoform was unique in
promoting PDGFRA transcription (Figure 6A), a possible
colocalization of AP-2 with the soluble ErbB4 ICD was ad-
dressed. Confocal microscopy of COS-7 transfectants dem-
onstrated a partial colocalization of ErbB4 ICD, but not of
full-length noncleavable ErbB4 JM-b, with AP-2 in the nu-
clei (Figure 8A). Furthermore, both AP-2 as well as AP-2
associated with ErbB4 ICD but not with full-length ErbB4
JM-b in coprecipitation experiments (Figure 8B). GST pull-
down experiments confirmed an interaction between AP-2
and the N-terminal kinase region of ErbB4 ICD (Figure 8C,
lanes 1–3). As a control demonstrating a previously charac-
terized interaction (Aqeilan et al., 2005), Wwox was shown to
bind to the C-terminal part of ICD (Figure 8C, lanes 4–6).
Consistent with the effects of AP-2–specific RNA interfer-
ence on PDGFRA promoter activity (Figure 7D), both AP-2
and AP-2 increased the potential of ErbB4 ICD to stimulate
PDGFRA promoter activity in HEK-293T transfectants (Fig-
ure 8D). Interestingly, coexpression of AP-2 with nonstimu-
lated full-length ErbB4 did not result in enhanced promoter
activity (data not shown).
To address the functional significance of AP-2 on promot-
ing cellular growth downstream of the different ErbB4 iso-
forms, number of viable serum-starved NR6 transfectants
was estimated by MTT assays on 96-well plates in the pres-
ence of siRNA targeting AP-2 or nonsilencing siRNA con-
trol. The siRNA targeting AP-2 (42% knockdown) sup-
pressed the number of cells expressing JM-a CYT-2 but had
no significant effect on cells expressing JM-b CYT-2 (Figure
8E), consistent with the inability to JM-b CYT-2 to partially
colocalize (Figure 8A) and associate with (Figure 8B) with
AP-2.
These findings indicate that AP-2 promotes PDGFRA
transcription downstream of ErbB4 JM-a by directly in-
teracting with the soluble ICD in the nucleus. These data
Figure 6. Regulation of PDGFRA expression
by ErbB4 isoforms. (A) NR6 transfectants
were cultured for 8 h in the absence of serum,
stimulated for 2 h with or without 50 ng/ml
NRG-1, and analyzed for PDGFRA mRNA
expression by RT-PCR. (B) NR6 transfectants
were treated with or without 10 M AG 1478
for 8 h in the absence of serum. PDGFRA
mRNA expression was analyzed by RT-PCR.
(C) Cells were cultured overnight in the
presence or absence of 10% FCS. PDGFR-
protein expression was analyzed by West-
ern blotting with anti-PDGFR- antibody.
n.s., nonspecific band also present in the
vector control lanes. (D) Cells were starved
overnight without serum and stimulated
for 10 min with 0 or 50 ng/ml PDGF-BB.
PDGFR- tyrosine phosphorylation was ana-
lyzed by immunoprecipitation with an anti-
PDGFR- antibody followed by Western blot-
ting with an anti-phosphotyrosine antibody.
Membrane was reblotted with an anti-
PDGFR- antibody. (E) NR6 transfectants
were plated onto 24-well plates. The next day
the medium was replaced with serum-free
medium containing or not 20 M of PDGFR
inhibitor AG 1296 or 50 ng/ml PDGF-BB. Ad-
herent cells were counted at indicated time
points with hemocytometer. *p  0.05 for a
difference between AG 1296– or PDGF-BB–
treated and control cells. (F) NR6 cells ex-
pressing JM-a CYT-2 were cultured for 16 h in
the presence or absence of 20 M AG 1296 in serum-free medium. PDGFR- tyrosine phosphorylation was analyzed by immunoprecipitation
with an anti-PDGFR- antibody followed by Western blotting with an anti-phosphotyrosine antibody. Membrane was reblotted with an
anti-PDGFR- antibody. ErbB4 tyrosine phosphorylation was analyzed by Western blotting with a phospho-specific anti-ErbB4 antibody
followed by reblotting with an anti-ErbB4 antibody.
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also provide a mechanistic explanation for the observa-
tion that only the cleavable JM-a CYT-2 isoform promoted
PDGFRA transcription.
DISCUSSION
ErbB1 and ErbB2 receptors have successfully been used as
cancer drug targets in the clinic (Hynes and MacDonald,
2009). However, the biological role of ErbB4 and its potential
applicability as a cancer drug target has remained unclear
(Sundvall et al., 2008a; Hollmen and Elenius, 2010). Cur-
rently, there is no consensus about the cellular responses
stimulated via ErbB4. Several lines of evidence suggest that
ErbB4 induces differentiation (Chen et al., 1996; Jones et al.,
1999) or apoptosis (Arasada and Carpenter, 2005; Naresh et
al., 2006). However, ErbB4 has also been documented to
promote proliferation and tumor growth (Tang et al., 1999;
Alaoui-Jamali et al., 2003; Hollmen et al., 2009). One possible
explanation for the different conclusions is that the ERBB4
gene is spliced into four functionally unique isoforms (Junt-
tila et al., 2003; Maatta et al., 2006; Muraoka-Cook et al., 2009),
and most available data has been produced using undefined
reagents or analyzing different isoforms.
Here, two of the ErbB4 isoforms, JM-a CYT-2 and JM-b
CYT-2, were overexpressed in NR6 cells, and their signaling
responses were compared. JM-a CYT-2 has previously been
shown to promote survival and proliferation in myeloid and
breast cancer cells (Junttila et al., 2005; Maatta et al., 2006).
JM-a CYT-2 promoted survival also in NR6 fibroblasts upon
serum deprivation, but interestingly, JM-b CYT-2 induced
cell death. Consistent with differential roles also in vivo,
JM-a isoforms are frequently present in various types of
epithelial carcinomas at relatively high quantities, whereas
the JM-b isoforms are typically absent (Junttila et al., 2005;
Hollmen and Elenius, 2010; data not shown). In addition,
there is a selective up-regulation of the JM-a isoforms in
pediatric ependymoma when compared with normal brain
tissue (Gilbertson et al., 2002). These findings demonstrate
that ErbB4 isoforms may have significantly different biolog-
ical activities and indicate a selection pressure favoring ex-
pression of the survival-promoting JM-a isoform in malig-
nant cells.
The known functional difference between the JM-a CYT-2
and JM-b CYT-2 isoforms is that the 23 unique amino acids
in the extracellular juxtamembrane region of JM-a provide a
proteinase cleavage site that is missing from the alternative
13 amino acids of JM-b (Elenius et al., 1997). As a conse-
quence, only isoforms of the JM-a type may signal via a
mechanism involving a two-step proteolytic cleavage gen-
erating a soluble ICD (Ni et al., 2001; Maatta et al., 2006). In
accordance, only NR6 transfectants expressing JM-a CYT-2
demonstrated efficient ligand-independent accumulation of
a highly tyrosine-phosphorylated and kinase active 80-kDa
proteolytic fragment. These observations implicate a role for
the release of the soluble ICD solely from the JM-a CYT-2
isoform as a mechanism causally involved in the differential
cellular functions promoted by the two isoforms. Address-
ing the significance of ErbB4 cleaving enzymes on the cel-
lular responses of NR6 transfectants using inhibitors of ei-
ther TACE or -secretase was precluded by the significant
background effects of these compounds on the parental NR6
cell line (data not shown). Consistent with the role of JM-a
Figure 7. Regulation of PDGFRA transcrip-
tion by ErbB4 activity. (A) SK-N-MC human
neuroblastoma cells were treated for 48 h
with or without control or ErbB4-specific
siRNAs. Relative PDGFRA and ERBB4
mRNA expression was analyzed by real-
time RT-PCR and normalized to the expres-
sion of the reference gene -actin. (B) MCF-7
breast cancer cells were transfected with
the PDGFRA promoter luciferase reporter
constructs pSLA4PDGFRluc–441/118 (441),
pSLA4PDGFRluc–944/118 (944), or
pSLA4PDGFRluc–1253/118 (1253) together
with a plasmid encoding EGFP. Cells starved
for 16 h were treated for 2 h with or without
80 ng/ml NRG-1 to activate ErbB4 or for 18 h
with 10 M retinoic acid (RA) as a positive
control known to stimulate PDGFRA pro-
moter activity. Columns represent relative lu-
ciferase activity of promoter constructs nor-
malized by the EGFP fluorescence signal (no
treatment 	 100% for each experiment). (C)
MCF-7 cells expressing pSLA4PDGFRluc–
1253/118 were treated for 48 h with or with-
out control or ErbB4-specific siRNAs, starved
for 16 h, and treated for 2 h with 0 or 80
ng/ml NRG-1. Columns represent relative lu-
ciferase activity of promoter constructs nor-
malized by the EGFP fluorescence signal. (D)
MCF-7 cells expressing pSLA4PDGFRluc–
1253/118 were treated for 48 h with control
siRNA or siRNAs targeting the indicated
transcription factors (TF), starved for 16 h and
treated for 2 h with 0 or 80 ng/ml NRG-1.
PDGFRA promoter activity was determined as in C. The values represent the effect of NRG-1 treatment as percentages of the control siRNA
sample. The transcription factor mRNA expression levels, as determined by real-time RT-PCR, are shown relative to control siRNA treatment
(TF mRNA %).
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isoform cleavage in promoting growth, however, an anti-
body specifically recognizing the JM-a isoform and prevent-
ing its cleavage suppresses the growth of breast cancer cells
(Hollmen et al., 2009).
To further characterize the molecular mechanisms under-
lying the functional differences between the cleavable and
noncleavable ErbB4 isoforms, gene expression patterns of
NR6 transfectants were compared using cDNA microarrays.
Figure 8. Selective and functional association of soluble ErbB4 ICD with AP-2. (A) COS-7 cells were transfected with pcDNA3.1ICD2-HA
or pcDNA3.1ErbB4JM-bCYT-2-HA, stained with anti-HA (green) and anti-AP-2 (red) antibodies. The nuclei were stained with DAPI (blue).
The cells were visualized by confocal microscopy. Bar, 10 m. (B) COS-7 cells were transiently transfected with constructs encoding
HA-tagged ErbB4 JM-b CYT-2 or ErbB4 ICD2 and Myc-tagged AP-2 or AP-2-. Lysates were immunoprecipitated with anti-Myc antibody
and anti-HA antibody was used in Western blotting. Expression levels were controlled by Western analysis with anti-HA and anti-Myc
antibodies. (C) GST fusion proteins including the whole intracellular domain of the CYT-2-type (ICD), N-terminally truncated ICD (ICD-N),
or C-terminally truncated ICD (ICD-C) were incubated with lysates of COS-7 cells transiently expressing Myc-tagged AP-2 or Wwox.
Material precipitating with glutathione Sepharose beads was analyzed by Western blotting with anti-Myc antibody. Membranes were reblotted
with anti-GST antibody. (D) HEK-293T cells were cotransfected with the PDGFRA promoter-luciferase construct pSLA4PDGFRluc–1253/118 and
a construct encoding Renilla luciferase together with an empty vector, constructs encoding the ErbB4 ICD of CYT-2-type (ICD), AP-2, or
AP-2, or a combination of constructs encoding ICD and AP-2. Columns represent relative luciferase activity of the PDGFRA promoter
construct normalized by fluorescence signal from the Renilla luciferase. (E) NR6 cells stably expressing JM-a CYT-2 or JM-b CYT-2 were
transfected with siRNA targeting AP-2 or with a nonsilencing control siRNA. After siRNA transfection the cells were starved for 3 d, and
the number of viable cells was determined with MTT assay. *p  0.05.
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The analysis indicated PDGFRA as one of the target genes
that was differentially regulated by JM-a CYT-2 and JM-b
CYT-2. Experiments with a chemical inhibitor of the
PDGFR- kinase that suppressed the survival effect of JM-a
CYT-2 further suggested a functional link between
PDGFR- up-regulation and ErbB4 JM-a CYT-2 expression.
In addition, PDGF-BB, an agonist of PDGFR-, rescued cells
from JM-b CYT-2–induced death. Interestingly, FCS used to
supplement cell culture media is known to be a rich source
of PDGF ligands (Ross et al., 1974). This may indicate that the
survival effects of ErbB4 isoforms were only observed after
serum starvation as the lack of medium-derived PDGF sen-
sitized cells to regulated PDGFR expression. Serum starva-
tion alone also up-regulated PDGFR- expression in the
vector control NR6 cells, putatively as an adaptation to low
extracellular ligand concentration (Lih et al., 1996), and this
up-regulation was further enhanced by the presence of
ErbB4 JM-a CYT-2, but was reversed by JM-b CYT-2. Previ-
ously NRG-1 has been shown to inhibit PDGF-BB–stimu-
lated vascular smooth muscle cell functions (Clement et al.,
2007), but a direct role of ErbB4 in regulation of PDGFR has
not been described. Our data indicate PDGFRA as one of the
target molecules differently regulated by ErbB4 isoforms
and suggest a major role for it in ErbB4 isoform specific
signaling responses leading to distinct behavior of the NR6
transfectants.
PDGFRA promoter assays in the presence and absence of
siRNAs targeting transcription factors with suggested inter-
actions with the PDGFRA promoter (Afink et al., 1995;
Kawagishi et al., 1995) identified AP-2 as a factor positively
regulating PDGFRA transcription. The specific association of
AP-2 with the cleaved ICD derived from ErbB4 JM-a was
indicated as the soluble ICD but not full-length ErbB4 1)
partially colocalized with AP-2 in the nucleus, 2) interacted
with AP-2 in coprecipitation and GST pull-down assays, and
3) had a synergistic effect with AP-2 on enhancing PDGFRA
promoter activity. Moreover, 4) siRNA targeting AP-2 effi-
ciently blocked the survival of cells expressing the cleavable
JM-a CYT-2 but not of cells expressing JM-b CYT-2. Both
AP-2 and AP-2 associated with ErbB4 ICD, although the
transcriptional synergism between the ICD and AP-2
seemed to be stronger compared with AP-2. In contrast,
full-length ErbB4 JM-b not capable of releasing a soluble
ICD fragment, did not demonstrate colocalization or associ-
ation with AP-2, and the viability of cells expressing the
JM-b isoform was not significantly affected by siRNA target-
ing AP-2. These findings support a model in which the sur-
vival-promoting effect of the JM-a CYT-2 isoform involves
up-regulation of PDGFRA transcription via a unique and direct
interaction of the released ICD fragment in the nucleus with
AP-2. The observations also imply that the survival-promot-
ing activity of the soluble ICD may, in the case of cleavable
ErbB4 JM-a, counterbalance death-promoting signaling
pathways, such as the Mek/Erk pathway, stimulated by all
full-length ErbB4 forms at the cell surface. Indeed, our un-
published observations indicate that targeting of Mek sig-
nificantly rescues cells expressing ErbB4 JM-b from starva-
tion-induced death.
In conclusion, we provide evidence of opposite cellular
functions promoted by alternatively spliced JM isoforms of
ErbB4. Recently, similar observations of dramatically differ-
ent cellular responses were reported for another pair of
ErbB4 isoforms, the CYT isoforms, which promote either
proliferation or differentiation in the mouse mammary gland
(Muraoka-Cook et al., 2009). Our findings with the AG 1478
compound indicated that a wide-spectrum ErbB kinase in-
hibitor could promote either cell death or survival depend-
ing on the type of ErbB4 isoform present. These data un-
derline the importance of investigating the basic cancer
biology of ErbB4 isoforms. Moreover, the findings indi-
cate that differential consequences of blocking different
ErbB4 isoforms should be taken into consideration when
developing novel diagnostic tests and therapeutics for
targeting ErbB receptors.
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